CDK4 and breast neoplasm: Our study suggests that the early identification of patients with a high ERα ENR of breast tumor cells, who may be resistant to ET, could lead to the inclusion of a CDK4/6 inhibitor or mTOR inhibitor in the treatment regimen [36].